Cargando…
1p/19q codeletion and RET rearrangements in small-cell lung cancer
The prognosis of small-cell lung cancer (SCLC) is poor despite reports suggesting modest improvement in survival. To date, chemotherapy remains the cornerstone treatment for SCLC patients, and many studies have focused on identifying the molecular characteristics of SCLC, which serve as the basis fo...
Autores principales: | Lu, Hongyang, Xu, Haimiao, Xie, Fajun, Qin, Jing, Han, Na, Fan, Yun, Mao, Weimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913998/ https://www.ncbi.nlm.nih.gov/pubmed/27366094 http://dx.doi.org/10.2147/OTT.S108781 |
Ejemplares similares
-
Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic
por: Li, Yan-Xi, et al.
Publicado: (2016) -
Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018) -
Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018) -
Current management of RET rearranged non-small cell lung cancer
por: Stinchcombe, Thomas E
Publicado: (2020) -
How I treat anaplastic glioma without 1p/19q codeletion
por: Berghoff, Anna, et al.
Publicado: (2019)